The CCG is mandated with providing sustainable and scalable clinical diagnostic genomic testing for the BC population.
The CCG aims to implement emerging technologies to provide the most cost-effective clinical testing for genetic disease. The CCG will embrace personalized medicine through a strong integration of technology and informatics.
CCG successfully maintains CAP accreditation
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to CCG based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. The inspection included examination of the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examined laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. CCG was first accredited in 2011 and is one of more than 7,600 CAP-accredited facilities worldwide. More information can be found at www.cap.org.
We have received funding from Genome BC to carry out a project entitled Application of DNA microarray technologies to clinical testing in hereditary cancer syndromes. This will enable the improvement of our 14 gene panel to detect copy number alterations (CNA) using a platform which is scalable and sustainable.
More information can be found on Genome BC's website
The Centre for Clinical Genomics (CCG) is pleased to announce its 14 gene Hereditary Cancer Panel is now available to patients. This panel replaced BRCA1/2 testing in British Columbia in October 2014. See this page for details.
The Excellence in BC Health Care Awards honoured CCG with a 2014 Golden Apple Award for Top Innovation - Health Authority. Presented by the Health Employers Association of British Columbia (HEABC), the Awards reward innovation and best practices within BC's publicly funded health care providers.